7 recruiting. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 7 |
| Phase 2 | 2 | Recruiting 2 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia RD13-02 - Severe Aplastic Anemia, Relapse | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 15 | 2025-06-19 | 2025-07-24 |
| Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML CVA - Acute Myeloid Leukemia, Relapse | Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2025-03-15 | 2025-02-24 |
| Autologous CAR-T Cells Targeting B7-H3 in PDAC iC9-CAR.B7-H3 T cell infusion - Pancreas Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-18 | 2026-06-08 |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells iC9-CAR.B7-H3 T Cell Therapy, cyclophosphamide, fludarabine - Breast Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 42 | 2024-06-27 | 2026-07-28 |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells Chemotherapy, Cell infusion - Hodgkin Lymphoma, Relapse | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 31 | 2024-04-25 | 2026-08-06 |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Cyclophosphamide, Fludarabine, Cell Therapy - Head and Neck Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 33 | 2024-04-05 | 2026-09-16 |
| IA Carboplatin + Radiotherapy in Relapsing GBM IA Carbo+ Radiation - Glioblastoma Multiforme, Relapse | Phase 1 / Phase 2 | Recruiting | Université de Sherbrooke | 35 | 2018-07-10 | 2025-08-11 |
Recurrence (7) · Anemia, Aplastic (1) · Breast Neoplasms (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Disease Attributes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Neoplasms (5) · Hemic and Lymphatic Diseases (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Hematologic Diseases (2) · Anemia (1) · Astrocytoma (1) · Bone Marrow Diseases (1) · Bone Marrow Failure Disorders (1) · Breast Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Cell- and Tissue-Based Therapy (2) · Cyclophosphamide (2) · fludarabine (2) · fludarabine phosphate (2) · Drug Therapy (1) · Insulin Infusion Systems (1)
UNC Lineberger Comprehensive Cancer Center (4) · Institute of Hematology & Blood Diseases Hospital, China (1) · The First Affiliated Hospital of Xiamen University (1) · Université de Sherbrooke (1)
United States (4) · China (2) · Canada (1)
Ashwin Somasundaram, MD (1) · Bing Xu (1) · David Fortin, MD (1) · Jared Weiss, MD (1) · Natalie Grover, MD (1) · Yara Abdou, MD (1)
PMID 19534336, PMID 19760366, PMID 22284691, PMID 22931705, PMID 23844725, PMID 24026531, PMID 24947313
P50CA058223 (1), R01CA296807 (1)